Published in Lancet on June 27, 2011
Detection of C-peptide in Youth With Longstanding Type 1 Diabetes Mellitus | NCT02131675
Type 1 diabetes. Lancet (2013) 3.45
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest (2012) 1.84
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol (2013) 1.65
Reversal of type 1 diabetes via islet β cell regeneration following immune modulation by cord blood-derived multipotent stem cells. BMC Med (2012) 1.44
Combination therapy with an anti-IL-1β antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model. Diabetes (2014) 1.42
Management of diabetes mellitus in infants. Nat Rev Endocrinol (2011) 1.40
Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes (2013) 1.30
Optimization of current and future therapy for autoimmune diseases. Nat Med (2012) 1.29
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia (2012) 1.29
Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease. Diabetes Care (2015) 1.25
Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest (2014) 1.22
Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med (2012) 1.18
Treating human autoimmunity: current practice and future prospects. Sci Transl Med (2012) 1.16
Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol (2013) 1.13
Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes Metab Syndr Obes (2014) 1.11
Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes. Diabetes (2012) 1.07
Progress in immune-based therapies for type 1 diabetes. Clin Exp Immunol (2013) 1.06
Immune therapy in type 1 diabetes mellitus. Nat Rev Endocrinol (2013) 1.02
Latent autoimmune diabetes of the adult: current knowledge and uncertainty. Diabet Med (2015) 1.02
Remission without insulin therapy on gluten-free diet in a 6-year old boy with type 1 diabetes mellitus. BMJ Case Rep (2012) 1.00
On the etiology of type 1 diabetes: a new animal model signifying a decisive role for bacteria eliciting an adverse innate immunity response. Am J Pathol (2012) 0.95
The rise of multiple imputation: a review of the reporting and implementation of the method in medical research. BMC Med Res Methodol (2015) 0.94
Vaccine against autoimmune disease: antigen-specific immunotherapy. Curr Opin Immunol (2013) 0.94
Combining antigen-based therapy with GABA treatment synergistically prolongs survival of transplanted ß-cells in diabetic NOD mice. PLoS One (2011) 0.92
Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med (2012) 0.92
Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol (2012) 0.91
Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. Diabetes Care (2015) 0.91
Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes. PLoS One (2011) 0.89
Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes (2014) 0.87
Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes. Clin Exp Immunol (2013) 0.86
Antigen-specific therapeutic approaches in Type 1 diabetes. Cold Spring Harb Perspect Med (2012) 0.85
Clinical immunologic interventions for the treatment of type 1 diabetes. Cold Spring Harb Perspect Med (2012) 0.85
GAD65 autoantibodies and its role as biomarker of Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA). Drugs Future (2011) 0.84
Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes. J Mol Cell Biol (2011) 0.84
Comparative analysis of different biofactories for the production of a major diabetes autoantigen. Transgenic Res (2013) 0.83
New and future immunomodulatory therapy in type 1 diabetes. Trends Mol Med (2012) 0.83
Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector. Mol Ther (2015) 0.83
Coeliac disease and rheumatoid arthritis: similar mechanisms, different antigens. Nat Rev Rheumatol (2015) 0.83
Dead or alive? Diabetes Care (2012) 0.82
Diabetes: type 1 diabetes mellitus--a door opening to a real therapy? Nat Rev Endocrinol (2011) 0.81
Can we vaccinate against Type 1 diabetes? F1000 Biol Rep (2012) 0.81
Arresting type 1 diabetes after diagnosis: GAD is not enough. Lancet (2011) 0.80
Type 1 diabetes: A predictable disease. World J Diabetes (2015) 0.80
Biomarkers in type 1 diabetes: application to the clinical trial setting. Curr Opin Endocrinol Diabetes Obes (2014) 0.80
Prevention or early cure of type 1 diabetes by intranasal administration of gliadin in NOD mice. PLoS One (2014) 0.79
Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience. Rev Diabet Stud (2012) 0.79
Prevention of type 1A diabetes mellitus. Endocr Pract (2012) 0.79
Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes. Clin Exp Immunol (2013) 0.79
Hair regrowth in alopecia areata patients following Stem Cell Educator therapy. BMC Med (2015) 0.79
Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial. Diabetes Care (2013) 0.78
Non-antigenic and antigenic interventions in type 1 diabetes. Hum Vaccin Immunother (2013) 0.78
Immune therapy for treating type 1 diabetes: challenging existing paradigms. J Clin Invest (2014) 0.78
A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice. Sci Rep (2015) 0.78
Stem cell treatment for type 1 diabetes. Front Cell Dev Biol (2014) 0.77
Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials. Pediatr Diabetes (2013) 0.77
Identification of Candidate Tolerogenic CD8(+) T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model. J Diabetes Res (2016) 0.77
Beta cell antigens in type 1 diabetes: triggers in pathogenesis and therapeutic targets. F1000Res (2016) 0.77
Staging the progression to type 1 diabetes with prediagnostic markers. Curr Opin Endocrinol Diabetes Obes (2016) 0.77
Galantamine Attenuates Type 1 Diabetes and Inhibits Anti-Insulin Antibodies in Non-Obese Diabetic Mice. Mol Med (2015) 0.76
Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth. Diabetes Technol Ther (2013) 0.76
Metabolic syndrome - Removing roadblocks to therapy: Antigenic immunotherapies. Mol Metab (2014) 0.76
Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations. Bone Marrow Transplant (2015) 0.76
Prophylactic Injection of Recombinant Alpha-Enolase Reduces Arthritis Severity in the Collagen-Induced Arthritis Mice Model. PLoS One (2015) 0.76
Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care (2016) 0.76
Trials in the prevention of type 1 diabetes: current and future. Can J Diabetes (2014) 0.76
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going? Pharmacol Res (2015) 0.76
Targeting Homeostatic T Cell Proliferation to Control Beta-Cell Autoimmunity. Curr Diab Rep (2016) 0.76
Antigen-based vs. systemic immunomodulation in type 1 diabetes: the pros and cons. Islets (2013) 0.76
Clinical potential of antigen-specific therapies in type 1 diabetes. Rev Diabet Stud (2012) 0.76
Immunotherapy for type 1 diabetes. J Endocrinol Invest (2017) 0.76
Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes. Front Immunol (2017) 0.75
T-cell Metabolism as a Target to Control Autoreactive T Cells in β-Cell Autoimmunity. Curr Diab Rep (2017) 0.75
Modulation of Autoimmune T-Cell Memory by Stem Cell Educator Therapy: Phase 1/2 Clinical Trial. EBioMedicine (2015) 0.75
Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes. Pediatr Diabetes (2015) 0.75
Inducing immune tolerance: a focus on Type 1 diabetes mellitus. Diabetes Manag (Lond) (2013) 0.75
A model-based approach to sample size estimation in recent onset type 1 diabetes. Diabetes Metab Res Rev (2016) 0.75
MAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD mice. Autoimmunity (2014) 0.75
Antigen-based immunotherapy for autoimmune disease: current status. Immunotargets Ther (2014) 0.75
ω-3 polyunsaturated fatty acids ameliorate type 1 diabetes and autoimmunity. J Clin Invest (2017) 0.75
Implication of the intestinal microbiome as a potential surrogate marker of immune responsiveness to experimental therapies in autoimmune diabetes. PLoS One (2017) 0.75
Latent Autoimmune Diabetes in Adults: Autoimmune Diabetes in Adults with Slowly Progressive β-cell Failure. Diabetes Metab J (2012) 0.75
Progress and challenges for treating Type 1 diabetes. J Autoimmun (2016) 0.75
Multipeptide-coupled nanoparticles induce tolerance in 'humanised' HLA-transgenic mice and inhibit diabetogenic CD8(+) T cell responses in type 1 diabetes. Diabetologia (2017) 0.75
Tolerogenic Nanoparticles to Treat Islet Autoimmunity. Curr Diab Rep (2017) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med (2005) 10.16
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature (1990) 6.71
Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet (2001) 6.14
Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med (1998) 6.13
GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med (2008) 5.74
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005) 5.04
Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care (2003) 4.92
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet (2011) 4.30
Oral tolerance. Immunol Rev (2005) 3.48
Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med (1990) 3.21
Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care (2008) 2.87
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care (2010) 2.57
Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med (1996) 2.35
Prediction and pathogenesis in type 1 diabetes. Immunity (2010) 2.26
Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet (1986) 2.10
Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Lancet (2000) 2.07
Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity (2010) 1.98
Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes (2011) 1.77
Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol (2010) 1.57
No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia (2000) 1.48
Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes (1998) 1.47
Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications (2005) 1.42
Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes (2010) 1.40
Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci (2008) 1.19
Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep (2008) 1.15
Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum (2001) 1.09
Antigen-specific immunotherapy for autoimmune diseases. Expert Opin Biol Ther (2007) 0.84
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med (2008) 17.19
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 14.33
Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science (2008) 14.26
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Promoting coherent minimum reporting guidelines for biological and biomedical investigations: the MIBBI project. Nat Biotechnol (2008) 12.96
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med (2002) 8.84
Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med (2011) 8.54
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer (2005) 5.57
Autoimmune polyendocrine syndromes. N Engl J Med (2004) 5.11
Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care (2005) 5.04
The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care (2009) 4.93
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78
Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care (2003) 4.50
C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes (2004) 4.44
Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet (2011) 4.30
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 4.15
Human oocytes reprogram somatic cells to a pluripotent state. Nature (2011) 4.03
Control of TH17 cells occurs in the small intestine. Nature (2011) 4.03
Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care (2013) 3.89
Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation (2007) 3.88
Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med (2005) 3.83
Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Arch Intern Med (2007) 3.58
Usability in the real world: assessing medical information technologies in patients' homes. J Biomed Inform (2003) 3.45
Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A (2009) 3.43
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol (2009) 3.30
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med (2002) 3.18
Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes (2012) 3.11
Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res (2010) 3.08
Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) Project: rationale and design. J Am Med Inform Assoc (2001) 3.06
TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest (2005) 3.04
Toward defining the autoimmune microbiome for type 1 diabetes. ISME J (2010) 3.03
A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus. J Am Med Inform Assoc (2005) 3.01
The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes (2006) 3.00
Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther (2005) 2.98
Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care (2009) 2.91
Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Mol Genet Metab (2008) 2.90
A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus: 5 year results of the IDEATel study. J Am Med Inform Assoc (2009) 2.90
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther (2013) 2.85
Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood (2009) 2.79
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care (2013) 2.73
Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab (2010) 2.70
A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care (2007) 2.67
Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation (2008) 2.65
Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study. Pediatr Diabetes (2005) 2.64
The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. Pediatr Diabetes (2008) 2.60
Insulin secretion in type 1 diabetes. Diabetes (2004) 2.59
Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care (2010) 2.57
Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes (2006) 2.52
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet (2013) 2.45